F17464 is a dopamine D3 receptor preferential antagonist exhibiting high affinity for human dopamine receptor subtype 3 (hD3) (Ki=0.17 nM) and 5-HT1a (Ki=0.16 nM) and a >50 fold lower affinity for the human dopamine receptor subtype 2 short and long form (hD2s/l) (Ki=8.9 and 12.1 nM, respectively).
F17464 is a D3 receptor antagonist, 5-HT1a receptor partial agonist.
F17464 blocks ketamine induced morphological changes, an effect D3 receptor mediated, in human dopaminergic neurons. F17464 increases dopamine release in the rat prefrontal cortex and mouse lateral forebrain-dorsal striatum and seems to reduce the effect of MK801 on % c-fos mRNA medium expressing neurons in cortical and subcortical regions.
F17464 also rescues valproate induced impairment in a rat social interaction model of autism, with dose range 0.32-2.5 mg/kg i.p. in both rats and mice
Cat.No
DC73426
Name
F17464
Chemical Properties
CAS
1268334-26-4
Formula
C25H30CLN3O6S
MW
536.04
Storage
References
1. Bitter I, et al. Neuropsychopharmacology. 2019 Oct;44(11):1917-1924.
2. Cosi C, et al. Eur J Pharmacol. 2021 Jan 5;890:173635.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
